Faldaprevir was an experimental drug for the treatment of hepatitis C (HCV). It was being developed by

Boehringer-Ingelheim C.H. Boehringer Sohn AG & Co. is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical ...

and reached Phase III

clinical trial Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, diet ...

s in 2011. Boehringer announced in 2014 that it would not pursue approval of the drug any more because of better HCV treatments having become available.

Mechanism of action

Faldaprevir is a

hepatitis C virus The hepatitis C virus (HCV) is a small (55–65 nm in size), enveloped, positive-sense single-stranded RNA virus of the family '' Flaviviridae''. The hepatitis C virus is the cause of hepatitis C and some cancers such as liver cancer (hepatoc ...

protease inhibitor.

Studies

Faldaprevir was tested in combination regimens with

pegylated interferon Pegylated interferon (PEG-IFN) is a class of medication that includes three different drugs as of 2012: * Pegylated interferon-alpha-2a * Pegylated interferon-alpha-2b * Pegylated interferon-beta-1a In these formulations, Polyethylene glycol (PEG ...

and

ribavirin Ribavirin, also known as tribavirin, is an antiviral medication used to treat RSV infection, hepatitis C and some viral hemorrhagic fevers. For hepatitis C, it is used in combination with other medications such as simeprevir, sofosbuvir, pe ...

, and in interferon-free regimens with other direct-acting antiviral agents including

deleobuvir Deleobuvir (formerly BI 207127) was an experimental drug for the treatment of hepatitis C. It was being developed by Boehringer Ingelheim. It is a non-nucleoside hepatitis C virus NS5B polymerase inhibitor. Deleobuvir was tested in combinati ...

. Data from the SOUND-C2 study, presented at the 2012 AASLD Liver Meeting, showed that a triple combination of faldaprevir, deleobuvir, and ribavirin performed well in HCV genotype 1b patients.

References

External links

Faldaprevir
at chem.sis.nlm.nih.gov

at chemicalregister.com {{RNA antivirals Abandoned drugs Cyclopropanes NS3/4A protease inhibitors Quinolines Tert-butyl compounds Vinyl compounds Thiazoles Carboxamides Bromoarenes Cyclopentyl compounds Pyrrolidines Carbamates